

CTI - Hyperlipidaemia February 2010

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking February 2010

The table below highlights the ongoing trials whose status has changed during February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700038410	Aspirin Omega-3-ethylester-concentrate	Completed	I/II	Aspirin, omega 3-ethylester concentrate: pharmacodynamics Effects on aspirin resistance Alone or in combination	GlaxoSmithKline
2 700030088	Atorvastatin	Discontinued	II	Atorvastatin: therapeutic use Heart failure Effects on vascular properties in patients with diastolic disease: Efficacy and quality-of-life effects	
3 700028371	Atorvastatin Fluvastatin Pitavastatin Pravastatin	Completed	IV	Atorvastatin, fluvastatin, pitavastatin, pravastatin: therapeutic use Atherosclerosis Intensive vs moderate lipid lowering in patients with acute coronary syndromes	
4 700040396	Cardiovascular-therapies	Completed	III	Cardiovascular therapies: therapeutic use Prevention of cardiovascular disorders Fixed-dose combination medication in those at raised risk of cardiovascular disease	
5 700042488	Colestilan Simvastatin	Active, no longer recruiting	III	Colestilan vs simvastatin: therapeutic use Dyslipidaemias In patients with chronic kidney disease on dialysis	Mitsubishi Pharma Europe, Mitsubishi Tanabe Pharma Corporation
6 700032078	Dalcetrapib	Active, no longer recruiting	III	Dalcetrapib: therapeutic use Acute coronary syndromes In patients receiving standard treatment	Roche
7 700052437	Docosahexaenoic-acid Eicosapentaenoic-acid	Recruiting	IV	Eicosapentaenoic acid + docosahexaenoic acid: therapeutic use Hyperlipidaemia In patients with HIV infection	
8 700030982	Fenofibrate	Active, no longer recruiting	IV	Fenofibrate: pharmacodynamics Effect of genotype on triglyceride-lowering response In volunteers	
9 700039959	Fenofibrate Tibolone	Completed	IV	Tibolone +/- fenofibrate: pharmacodynamics Effects on high-density lipoprotein cholesterol	

CTI - Hyperlipidaemia February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
10 700048319	Gemfibrozil SAM-531	Completed	I	SAM-531 + gemfibrozil: pharmacokinetics Potential Pharmacokinetic Interaction In volunteers	Wyeth
11 700029941	Metformin Omega-3-ethylester- concentrate	Active, no longer recruiting	III	Metformin +/- omega-3-ethylester concentrate: pharmacodynamics Effects of fatty acid delivery on myocardial metabolism and function In patients with type 2 diabetes mellitus	
12 700034849	RVX-208	Active, no longer recruiting	II	RVX 208: therapeutic use Atherosclerosis Phase IIb study in patients with stable coronary disease: ASSERT	Resverlogix Corporation
13 700051873	RVX-208	Recruiting	II	RVX 208: therapeutic use Coronary artery disease In patients with unstable disease: ASSURE-1 IVUS study	Resverlogix Corporation
14 700049560	SLV-342	Recruiting	I	SLV 342: adverse reactions Various toxicities In volunteers	Solvay Pharmaceuticals

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.